Menu Search
Equities

IDEAYA Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
30J:FRA

IDEAYA Biosciences Inc

Actions
  • Price (EUR)27.80
  • Today's Change0.20 / 0.72%
  • Shares traded50.00
  • 1 Year change+28.70%
  • Beta0.0851
Data delayed at least 15 minutes, as of Feb 11 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

  • Revenue in USD (TTM)214.83m
  • Net income in USD-160.74m
  • Incorporated2015
  • Employees131.00
  • Location
    IDEAYA Biosciences Inc7000 SHORELINE CT, SUITE 350SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 443-6209
  • Fax+1 (302) 655-5049
  • Websitehttps://www.ideayabio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.